Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Major depressive disorder (MDD) is a common non-motor symptom in Parkinson's disease (PD), affecting one third of patients. Dopaminergic deficits have been hypothesised to contribute to PD-MDD, but direct molecular evidence is limited. In this cross-sectional study, we compared striatal dopamine transporter (DAT) binding between 22 depressed (DSM-5) and 34 well-matched non-depressed PD patients using [18F]FE-PE2I PET. The striatum was segmented into ventral striatum, medial caudate, anterior putamen and posterior putamen. Mixed-effect models included region, hemisphere, and group as fixed effects, and subject ID as random effect. PD-MDD patients showed lower DAT binding in the ventral striatum (P = 0.016), but not in caudate or putamen, driving a significant group × region interaction (P = 0.012). Within the depressed group, greater depression severity was paradoxically associated with higher ventral striatal DAT binding (P = 0.039). These findings provide in vivo evidence linking ventral striatal dopaminergic dysfunction to PD-MDD, advancing mechanistic understanding relevant for treatment development.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.